熱門資訊> 正文
IMNN-001第二阶段研究结果显示，Imunon股价上涨157%
2024-07-30 22:09
- Shares of Imunon (NASDAQ:IMNN) rallied 157% Tuesday after the company released positive topline results from a Phase 2 study of its drug IMNN-001 in the treatment of ovarian cancer.
- The study showed an increase of 11.1 months in overall survival in patients with newly diagnosed, advanced ovarian cancer who were treated with the drug compared with standard of care alone, according to a statement.
- Imunon said it expects to start a registrational study of IMNN-01 in Q1 2025.
More on Imunon
- Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Imunon
- Historical earnings data for Imunon
- Financial information for Imunon
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
